A Comprehensive Monograph on Naltrexone: Pharmacology, Clinical Efficacy, and Therapeutic Applications

Drug Identification and Physicochemical Profile

Naltrexone is a small molecule drug that has become a cornerstone in the management of substance use disorders. Its unambiguous identification and characterization are fundamental to its application in clinical practice, pharmaceutical manufacturing, and research. This section details its nomenclature, molecular properties, and key physicochemical characteristics.

Nomenclature and Chemical Identifiers

Naltrexone is known by several names across chemical, pharmaceutical, and regulatory domains. Its primary non-proprietary name is Naltrexone.[1] The systematic name, according to the International Union of Pure and Applied Chemistry (IUPAC), is (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one.[3] An alternative systematic name frequently cited is 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one.[1]

Throughout its development and marketing, Naltrexone has accumulated numerous synonyms and brand names. Chemical synonyms include N-Cyclopropylmethylnoroxymorphone and N-Cyclopropylmethyl-14-hydroxydihydromorphinone.[1] Its developmental code was EN 1639A.[2] It is marketed globally under brand names such as Revia, Depade, Trexan, Vivitrol, Contrave (in combination with bupropion), Mysimba, Celupan, Nalorex, and Nemexin.[1] International non-proprietary names include Naltrexona (Spanish), Naltrexon (German), and Naltrexonum (Latin).[1]

For precise identification in scientific databases and regulatory filings, the following identifiers are used:

• DrugBank ID: DB00704 [1]
• CAS Number: 16590-41-3 for the free base form and 16676-29-2 for the hydrochloride salt.[2]
• Chemical Formula: C20​H23​NO4​ [1]
• InChI Key: DQCKKXVULJGBQN-XFWGSAIBSA-N [3]
• SMILES Code: C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O [3]

Molecular Structure and Properties

Naltrexone is structurally classified as an organic heteropentacyclic compound belonging to the morphinane class of molecules.[2] It is a synthetic congener of oxymorphone and is specifically a derivative of noroxymorphone.[1] Its structure is distinguished from the related opioid antagonist naloxone by the substitution of the N-allyl group with an N-cyclopropylmethyl group, a modification that contributes to its distinct pharmacological profile, including greater potency and a longer duration of action.[1]

The molecular weight of Naltrexone is a key parameter for dosage calculations and analytical chemistry. Its average molecular weight is 341.40 g/mol, and its monoisotopic mass is 341.162708229 Da.[1] The elemental analysis reveals a composition of Carbon (70.36%), Hydrogen (6.79%), Nitrogen (4.10%), and Oxygen (18.75%).[3]

Physicochemical Characteristics

The physical and chemical properties of Naltrexone dictate its formulation, stability, and behavior in biological systems. In its solid state, Naltrexone appears as crystals when purified from acetone or methanol, or as an off-white to yellow solid powder in its bulk form.[2] The melting point of the free base is in the range of 168–170 °C.[2] The hydrochloride salt, which is commonly used in pharmaceutical preparations, has a significantly higher melting point of 274–276 °C.[2]

A critical distinction exists in the solubility of Naltrexone's different forms. The free base is described as insoluble in water but soluble in organic solvents like ethanol and dimethyl sulfoxide (DMSO).[2] In contrast, Naltrexone hydrochloride exhibits high water solubility, reaching 100 mg/mL at 25 °C.[2] This marked difference in aqueous solubility is a pivotal factor in pharmaceutical formulation. The poor solubility of the free base makes it unsuitable for aqueous solutions required for injections or for rapid dissolution in the gastrointestinal tract. Consequently, the drug is almost universally prepared and administered as its hydrochloride salt to ensure adequate bioavailability and facilitate the creation of stable liquid formulations.

The drug's lipophilicity is moderate, with a partition coefficient (LogP) reported as 1.92, indicating its ability to cross lipid membranes.[2] Naltrexone is stable under recommended storage conditions, which are typically dry, dark, and refrigerated (0–4 °C for short-term storage) or frozen (-20 °C for long-term storage).[2] Its stability in solution has been demonstrated, as it can be mixed with juices or syrups to mask its bitter taste and remain stable for 60–90 days, a practical consideration for improving patient adherence, particularly in outpatient settings.[2]

Naltrexone is available as a high-purity pharmaceutical primary standard from the United States Pharmacopeia (USP), as well as a certified reference material, underscoring its role as a well-characterized compound for quality control and analytical assays in the pharmaceutical industry.[4]

Table 1: Physicochemical Properties of Naltrexone

Property	Value (Naltrexone Free Base)	Value (Naltrexone Hydrochloride)	Source(s)
CAS Number	16590-41-3	16676-29-2	2
Molecular Formula	C20​H23​NO4​	C20​H23​NO4​⋅HCl	1
Average Molecular Weight	341.40 g/mol	377.86 g/mol	1
Appearance	Crystals from acetone; Off-white to yellow powder	Crystals from methanol	2
Melting Point	168–170 °C	274–276 °C	2
Water Solubility	Insoluble	100 mg/mL at 25 °C	2
Partition Coefficient (LogP)	1.92	Not specified	2

Core Pharmacology

The clinical utility of Naltrexone is derived from its complex interactions with the body's endogenous opioid system. Its pharmacology is characterized by a potent antagonist mechanism at multiple opioid receptors, a distinct pharmacokinetic profile involving a crucial active metabolite, and a surprisingly long duration of action that belies its plasma half-life.

Mechanism of Action: A Multi-faceted Antagonist

Naltrexone's primary mechanism of action is as a pure, competitive opioid receptor antagonist.[1] It functions by physically occupying opioid receptors, primarily within the central nervous system (CNS), without activating them. This competitive binding effectively blocks both endogenous opioids, such as endorphins and enkephalins, and exogenous opioids, such as heroin, morphine, and oxycodone, from accessing and stimulating these receptors.[1]

The drug exhibits a clear hierarchy in its affinity for the different opioid receptor subtypes. It binds with the highest affinity to the mu-opioid receptor (MOR), which is the primary target for most clinically used and abused opioids and is central to their rewarding and analgesic effects.[1] Its affinity for the kappa-opioid receptor (KOR) is lower, and its affinity for the delta-opioid receptor (DOR) is substantially lower still.[1] Naltrexone has also been shown to possess antagonist activity at the sigma non-opioid intracellular receptor 1, though the clinical significance of this interaction is less defined.[1]

The characterization of Naltrexone as a "pure" or "silent" antagonist is an oversimplification. A more nuanced understanding reveals that it acts as a weak partial agonist at all three major opioid receptors. Studies have measured maximal effect (Emax​) values of 14% to 29% at the MOR, 16% to 39% at the KOR, and 14% to 25% at the DOR.[5] This subtle intrinsic activity may contribute to some of its clinical effects beyond simple receptor blockade. Furthermore, its pharmacological identity can be context-dependent. In the presence of a full MOR agonist like morphine, Naltrexone appears to behave as an inverse agonist at the MOR.[5] An inverse agonist not only blocks the receptor but also reduces its basal, or constitutive, signaling activity. This property provides a compelling molecular explanation for Naltrexone's ability to precipitate an exceptionally severe and abrupt withdrawal syndrome in opioid-dependent individuals, as it would not only displace the agonist but also actively suppress the upregulated signaling state of the receptors.

Pharmacodynamics: The Clinical Consequences of Receptor Blockade

The receptor-level interactions of Naltrexone translate into profound and clinically relevant physiological and psychological effects.

In Opioid Use Disorder (OUD): By competitively occupying MORs, Naltrexone effectively prevents opioid drugs from producing their characteristic effects. It markedly attenuates or completely blocks euphoria, analgesia, respiratory depression, and miosis (pupil constriction).[1] This action removes the primary reinforcing properties (the "high") that drive opioid use. When administered chronically to a detoxified individual, it can help extinguish drug-seeking behavior and prevent the re-establishment of physical dependence.[1] The blockade is potent and long-lasting; a standard 50 mg oral dose is sufficient to block the pharmacological effects of a 25 mg intravenous dose of heroin for at least 24 hours, with higher doses providing blockade for 48 to 72 hours.[14]

In Alcohol Use Disorder (AUD): The mechanism in AUD is less direct but is fundamentally linked to the same opioid system. Alcohol consumption is known to trigger the release of endogenous opioids in the brain's reward pathways, which contributes significantly to the pleasurable and reinforcing effects of drinking.[1] Naltrexone works by blocking these endogenous opioids from binding to their receptors, particularly the MOR.[5] By interrupting this link in the reward cascade, Naltrexone blunts the feeling of euphoria and reduces the craving for alcohol.[10] Evidence also suggests it modifies the hypothalamic-pituitary-adrenal (HPA) axis, a key stress-response system, which may further contribute to its ability to suppress ethanol consumption.[12]

A key pharmacodynamic feature of Naltrexone is its prolonged receptor occupancy. Positron Emission Tomography (PET) imaging studies have shown that a single 50 mg dose can occupy 90-95% of brain MORs, and this blockade persists far longer than the drug's presence in the plasma would suggest.[5] The half-time of MOR blockade in the brain has been measured at 72 to 108 hours (3 to 4.5 days).[5] This durable receptor engagement is likely due to Naltrexone's very high receptor affinity and slow dissociation kinetics, and it is a cornerstone of its clinical utility, allowing for flexible dosing schedules and forming the basis for the long-acting injectable formulation.

Pharmacokinetics (ADME)

The journey of Naltrexone through the body—its absorption, distribution, metabolism, and excretion (ADME)—is characterized by rapid absorption, extensive metabolism, and the production of a key active metabolite.

Absorption: Following oral administration, Naltrexone is absorbed rapidly and almost completely from the gastrointestinal tract, with approximately 96% of the dose being absorbed.[1] However, it is subject to extensive first-pass metabolism in the liver. This means that a large fraction of the absorbed drug is metabolized before it reaches systemic circulation, resulting in a low and highly variable oral bioavailability, estimated to be between 5% and 40%.[1] Despite this, peak plasma concentrations of both Naltrexone and its primary metabolite are achieved within one hour of an oral dose.[14]

Distribution: Naltrexone is not highly bound to plasma proteins, with only 21% being bound over the therapeutic concentration range.[1] This low protein binding allows a larger fraction of the drug to be free and available to distribute into tissues and exert its pharmacological effect. It has a very large apparent volume of distribution (

Vd​) of 1350 L following intravenous administration, indicating that the drug distributes extensively throughout the body's tissues rather than remaining confined to the bloodstream.[1]

Metabolism: Naltrexone is extensively biotransformed, with over 98% of a dose being metabolized.[14] The primary site of metabolism is the liver, where it is converted to its major active metabolite, 6-β-naltrexol, through the reduction of its 6-keto group.[1] This reaction is catalyzed by cytosolic dihydrodiol dehydrogenase enzymes, not by the well-known Cytochrome P450 (CYP450) enzyme system.[13] The lack of involvement of the CYP450 system means Naltrexone has a lower potential for many common drug-drug interactions. The systemic clearance of Naltrexone (~3.5 L/min) is greater than the liver blood flow (~1.2 L/min), which strongly suggests that extra-hepatic sites of metabolism also exist.[1]

Excretion: The elimination of Naltrexone and its metabolites occurs primarily through the kidneys.[1] Between 53% and 79% of an administered dose is excreted in the urine, predominantly as metabolites like 6-β-naltrexol and its conjugated forms.[1] Very little of the parent drug is eliminated unchanged; urinary excretion of unmodified Naltrexone accounts for less than 2% of an oral dose.[1] Fecal excretion represents a minor elimination pathway.[1] The renal clearance for Naltrexone suggests elimination primarily by glomerular filtration, whereas the higher clearance for 6-β-naltrexol suggests an additional active tubular secretion mechanism.[14]

Half-Life: The elimination half-life of Naltrexone after oral administration is relatively short, approximately 4 hours.[1] In contrast, its active metabolite, 6-β-naltrexol, has a much longer half-life of 13 hours.[12] For the extended-release intramuscular injection (Vivitrol), the half-life is substantially longer, ranging from 5 to 10 days, reflecting the slow-release properties of the microsphere formulation.[12]

The Pivotal Role of the 6-β-Naltrexol Metabolite

It is impossible to fully understand the pharmacology of Naltrexone without considering the contribution of its principal metabolite, 6-β-naltrexol. The clinical activity of Naltrexone therapy is, in large part, a function of this active metabolite.

Due to the extensive first-pass metabolism of the parent drug, 6-β-naltrexol circulates in the plasma at concentrations that are 10- to 30-fold higher than those of Naltrexone at steady state.[18] This metabolite is not inert; it is a potent opioid antagonist in its own right, although its affinity for the MOR is roughly half that of Naltrexone.[1]

The combination of its high plasma concentrations and its long elimination half-life (13 hours vs. 4 hours for the parent drug) means that 6-β-naltrexol is a major contributor to the sustained antagonist effect of Naltrexone treatment.[1] Indeed, the overall duration of clinical action correlates much better with the pharmacokinetic profile of 6-β-naltrexol than with that of Naltrexone itself.[20]

This leads to a significant pharmacological observation: the apparent paradox between Naltrexone's short plasma half-life and its long clinical duration of action is resolved by a dual-mechanism phenomenon. The sustained clinical blockade is a product of both a pharmacokinetic property—the persistence of the long-acting, high-concentration active metabolite (6-β-naltrexol)—and a pharmacodynamic property—the high-affinity, slow-dissociation binding of the parent drug to the mu-opioid receptor.[5] This synergy explains why a single oral dose can be effective for 24-72 hours and why a monthly injection is a viable therapeutic strategy.

Furthermore, 6-β-naltrexol has a distinct pharmacodynamic profile. Unlike Naltrexone, which can act as an inverse agonist, 6-β-naltrexol is a neutral antagonist.[5] This means it blocks the receptor without affecting its basal activity, which may give it a lower intrinsic potential to precipitate withdrawal symptoms.[19] It also exhibits a degree of peripheral selectivity, meaning it has a stronger effect on opioid receptors outside the CNS (e.g., in the gut) compared to its central effects, a property not seen with Naltrexone.[19]

Approved Clinical Indications, Formulations, and Dosing

Naltrexone is a versatile therapeutic agent with well-established roles in addiction medicine and an emerging role in weight management. Its clinical application is defined by its FDA-approved indications, the availability of distinct oral and injectable formulations, and specific, safety-critical administration protocols.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved Naltrexone for three primary indications:

1. Alcohol Use Disorder (AUD): First approved for this indication in 1994, Naltrexone is used as an adjunctive therapy within a comprehensive treatment program that includes psychosocial support. It is intended to help individuals with alcohol dependence maintain abstinence or reduce heavy drinking.[1]
2. Opioid Use Disorder (OUD): Naltrexone received its initial FDA approval in 1984 for the treatment of OUD. Its specific indication is for the blockade of the effects of exogenous opioids, serving to prevent relapse in patients who have successfully undergone detoxification and are no longer physically dependent on opioids.[1]
3. Chronic Weight Management (Obesity): Naltrexone is a component of a fixed-dose combination product with the antidepressant bupropion. This combination, marketed as Contrave, is FDA-approved for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.[5]

Formulations and Brand Names

To meet different clinical needs, particularly regarding adherence, Naltrexone is available in two distinct formulations:

• Oral Tablets: This is the original formulation of the drug.
• Brand Names: The most common brand names for oral Naltrexone are Revia® and Depade®. An earlier brand name was Trexan®.[1] Generic versions are widely available.
• Strengths: Tablets are available in 25 mg, 50 mg, and 100 mg strengths, with the 50 mg tablet being the most commonly prescribed dose for daily administration.[6]
• Extended-Release Intramuscular (IM) Injection: This long-acting formulation was developed specifically to address the challenge of poor patient adherence to daily oral medication, which was a significant barrier to its effectiveness, especially in OUD.
• Brand Name: Vivitrol®.[1]
• Strength and Formulation: Vivitrol is supplied as a powder of naltrexone-containing microspheres that must be reconstituted and administered as a 380 mg intramuscular injection.[16]

Dosing and Administration Protocols

The administration of Naltrexone requires strict adherence to protocols to ensure safety and efficacy.

Critical Prerequisite: The Opioid-Free Period

The most critical safety consideration before initiating Naltrexone for any indication is ensuring the patient is completely free of physiological opioid dependence. Administering Naltrexone to an individual with opioids in their system will precipitate a severe, acute withdrawal syndrome. Therefore, a mandatory opioid-free "washout" period of a minimum of 7 to 10 days is required before the first dose.15 For individuals transitioning from long-acting opioids like methadone, this period may need to be extended to 14 days.28 Clinical confirmation of the opioid-free state, through a negative urine drug screen or a naloxone challenge test, is a standard prerequisite for treatment initiation.14

Dosing for Alcohol Use Disorder (AUD):

• Oral: The standard dose is 50 mg taken once daily.[12] To improve tolerability, particularly nausea, it can be taken with meals.[10] Flexible dosing schedules, such as 100 mg every other day or 150 mg every third day, may also be employed to enhance convenience and adherence.[12]
• Injectable (Vivitrol): The recommended dose is 380 mg administered via deep intramuscular injection once every 4 weeks (i.e., once a month).[16]

Dosing for Opioid Use Disorder (OUD):

• Oral: Treatment is often initiated with a lower test dose of 25 mg to confirm the absence of opioid dependence. If no withdrawal symptoms occur within one hour, the dose is typically increased to the standard maintenance dose of 50 mg once daily.[12] However, due to the high rates of non-adherence with daily oral medication in this population, oral Naltrexone is generally not considered a first-choice treatment for OUD.[26]
• Injectable (Vivitrol): The dose is 380 mg IM every 4 weeks.[16] The long-acting injectable formulation is the preferred method of administration for OUD, as it ensures sustained opioid blockade and bypasses the problem of daily adherence.[26]

Administration of Vivitrol (IM Injection):

The administration of Vivitrol is a medical procedure that must be performed by a healthcare provider. It involves specific techniques to maximize safety and efficacy. The injection must be delivered deep into the gluteal muscle.25 The injection site should be alternated between the right and left buttock for each subsequent monthly dose.31 It is crucial to use only the customized needles provided in the medication carton, as these are designed to ensure proper injection depth based on patient body habitus. Inadvertent injection into subcutaneous fat tissue instead of muscle significantly increases the risk of severe injection site reactions, including pain, induration, abscess formation, and tissue necrosis.25

Table 2: Naltrexone Formulations and Dosing Regimens

Indication	Formulation	Brand Name(s)	Standard Dosing Regimen	Key Administration Notes
Alcohol Use Disorder (AUD)	Oral Tablet	Revia, Depade, Generic	50 mg once daily.	Must be opioid-free for 7-10 days prior to initiation. Can be taken with food to reduce nausea.
	Extended-Release IM Injection	Vivitrol	380 mg IM every 4 weeks.	Must be opioid-free. Administered by a healthcare provider via deep gluteal injection.
Opioid Use Disorder (OUD)	Oral Tablet	Revia, Depade, Generic	25 mg test dose, then 50 mg once daily.	Must be opioid-free for 7-10 days. Not a first-line option due to adherence issues.
	Extended-Release IM Injection	Vivitrol	380 mg IM every 4 weeks.	Must be opioid-free. Preferred formulation for OUD. Administered by a healthcare provider.

Clinical Efficacy: An Evidence-Based Review

The clinical utility of Naltrexone is supported by a large body of evidence from decades of clinical trials. This section critically evaluates that evidence, examining its efficacy in its primary indications and comparing its performance against other standard-of-care pharmacotherapies.

Efficacy in Alcohol Use Disorder (AUD)

Naltrexone has been extensively studied for the treatment of AUD since the early 1990s. Numerous double-blind, placebo-controlled trials have consistently demonstrated its efficacy as an adjunct to psychosocial treatment.[32] The primary benefit of Naltrexone is not necessarily in promoting total abstinence, but rather in reducing the risk of relapse to

heavy drinking and decreasing the overall quantity of alcohol consumed by individuals who do drink.[5] While it can support abstinence, its effect on this outcome is generally considered more modest compared to its effect on heavy drinking patterns.[5]

The effectiveness of Naltrexone is significantly influenced by the type of concurrent psychosocial therapy provided. A meta-analysis of early trials revealed a crucial interaction: Naltrexone provided significant benefits over placebo when combined with therapies that taught patients coping skills for managing slips and relapses. In contrast, when combined with therapies that solely supported the goal of complete abstinence, Naltrexone showed no significant advantage over placebo.[5] This finding strongly supports the "pharmacological extinction" hypothesis, which posits that Naltrexone works best by being present when alcohol is consumed, thereby blocking the reinforcing reward and gradually extinguishing the learned association between drinking and pleasure.

The evidence base for Naltrexone in women with AUD is less extensive and has yielded mixed results. Systematic reviews of the available data suggest that Naltrexone may produce modest reductions in the quantity of alcohol consumed per drinking day, but its effect on the frequency of drinking or on abstinence rates in women is less clear.[36]

Both the oral tablet and the long-acting injectable (Vivitrol) formulations are considered effective for AUD.[15] One small study suggested that the intramuscular injection might lead to a longer time before a return to drinking compared to the oral formulation, likely due to guaranteed adherence.[15]

Efficacy in Opioid Use Disorder (OUD)

For OUD, Naltrexone's role is as a relapse prevention tool for individuals who are highly motivated and have already completed detoxification.[11] The primary challenge with the oral formulation has historically been poor adherence; patients who stop taking the daily pill are left unprotected against relapse. The development of the long-acting injectable formulation, Vivitrol, was a major advance that effectively solved this adherence problem, leading to significantly improved outcomes.[30]

Vivitrol has demonstrated particular efficacy in high-risk populations, such as individuals involved in the criminal justice system. Release from incarceration is a period of extremely high risk for opioid relapse and fatal overdose. Several clinical trials have shown that initiating extended-release Naltrexone prior to or immediately upon release from jail or prison significantly reduces rates of opioid relapse compared to standard care or treatment referrals alone.[30] In one pivotal multicenter trial involving ex-prisoners, the relapse rate at six months was 43% in the Vivitrol group versus 64% in the control group. Critically, there were zero overdose events in the Vivitrol group, compared to five in the control group, highlighting its life-saving potential in this vulnerable population.[30]

Despite its proven efficacy, a major practical barrier to the widespread use of Naltrexone for OUD is the difficult initiation process. The requirement for a 7- to 10-day period of complete opioid abstinence is often untenable for patients seeking treatment, leading to high rates of dropout before the first dose can even be administered.[41] This clinical challenge has spurred a shift in research focus from simply proving efficacy to optimizing real-world implementation. The recent Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT) trial (NCT04762537) directly addressed this barrier. The study found that a "rapid" initiation protocol, which shortens the process to 5-7 days using a careful titration of low-dose oral Naltrexone, was significantly more successful in starting patients on Vivitrol (62.7% success rate) than the standard, longer protocol (35.8% success rate).[41] While this rapid protocol required more intensive medical monitoring and was associated with a higher rate of adverse safety events, it represents a crucial step toward making Naltrexone a more accessible treatment option for OUD. This evolution in clinical trials—from asking

if a drug works to determining how to make it work best in clinical practice—reflects a maturation of the research field and is essential for translating a medication's potential into tangible public health benefits.

Comparative Effectiveness: Naltrexone vs. Acamprosate for AUD

For AUD, Naltrexone and Acamprosate are the two leading first-line pharmacotherapies. While both are effective, they operate through different mechanisms, which translates to different clinical strengths. This distinction is vital for personalizing treatment. Naltrexone, an opioid antagonist, is thought to work by reducing the rewarding, pleasurable effects of alcohol.[43] Acamprosate, a structural analogue of the neurotransmitter GABA, is believed to work by restoring the balance between the excitatory (glutamate) and inhibitory (GABA) systems in the brain, which are dysregulated by chronic alcohol use, thereby reducing the negative symptoms of protracted withdrawal.[43]

Meta-analyses of head-to-head and placebo-controlled trials have consistently supported this mechanistic differentiation. The findings indicate that Acamprosate is slightly more effective at promoting and maintaining complete abstinence from alcohol, with a number needed to treat (NNT) of 11 to prevent one person from returning to any drinking.[44] In contrast, Naltrexone is more effective at reducing craving and preventing a return to

heavy drinking in patients who have a slip, with an NNT of 11 to prevent one person from returning to heavy drinking.[10]

This evidence provides a clear framework for clinical decision-making. The choice between the two medications can be tailored to the patient's specific treatment goals. A patient whose primary goal is complete and total abstinence may be a better candidate for Acamprosate. Conversely, a patient who struggles with intense cravings and whose goal is to reduce heavy drinking and prevent dangerous binge episodes may derive more benefit from Naltrexone.

Table 3: Summary of Comparative Efficacy: Naltrexone vs. Acamprosate for AUD

Feature	Naltrexone	Acamprosate	Source(s)
Proposed Mechanism	Opioid antagonist; reduces rewarding effects and craving.	GABA/Glutamate modulator; reduces protracted withdrawal symptoms.	43
Primary Clinical Strength	Reducing heavy drinking and craving.	Promoting and maintaining complete abstinence.	44
Number Needed to Treat (NNT)	NNT = 11 to prevent return to heavy drinking.	NNT = 11 to prevent return to any drinking.	45

Comparative Effectiveness: Naltrexone vs. Buprenorphine for OUD

In the treatment of OUD, the primary comparison is between Naltrexone, a full opioid antagonist, and Buprenorphine (often co-formulated with naloxone), a partial opioid agonist.[23] This represents a fundamental difference in treatment philosophy: blocking the opioid system versus modulating it with a safer opioid.

Large, pragmatic, randomized controlled trials, such as the X:BOT study, have directly compared extended-release Naltrexone (XR-NTX) with sublingual Buprenorphine-naloxone (BUP-NX).[38] The results of these trials highlight a critical trade-off between the two medications.

The most significant difference lies in treatment initiation. The induction process for XR-NTX is substantially more difficult for patients to complete than for BUP-NX, primarily due to the required 7-10 day opioid-free period. Consequently, treatment initiation failure and dropout rates during the induction phase are significantly higher for XR-NTX.[38] However, for those patients who are successfully inducted onto either medication, their effectiveness in preventing relapse to illicit opioid use over the subsequent months is largely similar.[38]

This pattern is reflected in overall treatment retention rates. Network meta-analyses have shown that Buprenorphine is superior to Naltrexone in keeping patients engaged in treatment over time, with a risk ratio of 1.39 for retention favoring Buprenorphine.[50]

These findings have clear clinical implications. Buprenorphine's ease of initiation and superior retention rates make it a more accessible and often more appropriate first-line treatment for a broad range of patients with OUD. XR-Naltrexone serves as a highly effective and valuable alternative, particularly for specific patient populations: those who are highly motivated and can successfully navigate the induction period, those who have a strong preference for a non-agonist (non-opioid) therapy, or those in settings where the risk of medication diversion is a primary concern, such as the criminal justice system or for certain healthcare professionals.[29] The decision between these two effective medications requires a careful, shared decision-making process that balances the high barrier to entry for Naltrexone against its unique benefits as a non-addictive, long-acting antagonist.

Table 4: Summary of Comparative Efficacy: XR-Naltrexone vs. Buprenorphine for OUD

Feature	Extended-Release Naltrexone (Vivitrol)	Buprenorphine-Naloxone (Suboxone)	Source(s)
Mechanism of Action	Full Opioid Antagonist (blocks receptors)	Partial Opioid Agonist (partially activates receptors)	47
Treatment Initiation	Difficult; requires 7-10 day opioid-free period. High induction failure rate.	Easier; can be initiated once patient is in mild-moderate withdrawal.	38
Treatment Retention	Lower than Buprenorphine.	Superior to Naltrexone (RR = 1.39).	50
Relapse Prevention (Post-Induction)	Similar efficacy to Buprenorphine.	Similar efficacy to Naltrexone.	38
Clinical Niche	Patients preferring non-agonist therapy; settings with diversion concerns (e.g., criminal justice).	Broad first-line option due to ease of initiation and high retention.	48

Safety, Tolerability, and Risk Management

While Naltrexone is a valuable therapeutic tool, its use is associated with a distinct profile of adverse effects, contraindications, and critical safety risks that require careful management by clinicians and education for patients.

Adverse Effects Profile

Naltrexone is generally well-tolerated by most patients, but a range of side effects can occur.[52]

Common Side Effects: The most frequently reported adverse effects for both oral and injectable formulations include gastrointestinal and central nervous system symptoms. These commonly include nausea, headache, dizziness, anxiety, nervousness, insomnia or trouble sleeping, and fatigue or sedation.[5] Nausea is the single most common side effect and is often most pronounced at the beginning of treatment. It is typically mild and transient, and for the oral formulation, taking the dose with a meal can help mitigate this discomfort.[10] Other common effects include joint and muscle pain and decreased appetite.[28]

Injection-Specific Side Effects: The extended-release intramuscular injection (Vivitrol) is associated with a high incidence of injection site reactions. These are very common and can include pain, tenderness, swelling, redness (erythema), bruising, itching (pruritus), and the formation of a hard lump (induration) at the injection site in the buttock.[28] While most of these reactions are mild to moderate and resolve on their own, severe reactions can occur. These can include cellulitis, sterile abscess, hematoma, and, in rare cases, tissue necrosis that may require surgical debridement. The risk of these severe reactions is significantly increased if the injection is administered improperly into the subcutaneous fat layer instead of deep within the gluteal muscle.[16]

Serious Side Effects: Although less common, Naltrexone is associated with several serious potential adverse effects. There have been postmarketing reports of depression and suicidal thoughts or actions, though a direct causal relationship has not been definitively established. Nevertheless, this remains a key warning for the medication.[22] Eosinophilic pneumonia, a type of lung inflammation, has been reported in patients receiving the injectable formulation.[25] Severe allergic reactions, including anaphylaxis, are also possible.[28]

Contraindications and High-Risk Populations

The use of Naltrexone is strictly contraindicated in several specific clinical situations to prevent severe adverse events:

• Current Opioid Use: Naltrexone is absolutely contraindicated in patients who are currently receiving opioid analgesics for pain management, as it will block their therapeutic effect.[14]
• Opioid Dependence: It is contraindicated in patients with current physiological dependence on opioids. This includes individuals using illicit opioids as well as those maintained on opioid agonist therapies like methadone or partial agonist therapies like buprenorphine.[14]
• Acute Opioid Withdrawal: It must not be administered to patients who are actively experiencing symptoms of opioid withdrawal.[14]
• Failed Naloxone Challenge/Positive Opioid Screen: Any individual who has a positive urine screen for opioids or who exhibits withdrawal symptoms after a naloxone challenge test is not a candidate for Naltrexone initiation.[14]
• Severe Liver Disease: Naltrexone is contraindicated in patients with acute hepatitis or active liver failure due to its potential for hepatotoxicity.[5]
• Hypersensitivity: A history of a hypersensitivity reaction to Naltrexone or any of the components in its formulation is a contraindication.[14]

In addition to these absolute contraindications, Naltrexone should be used with caution in certain high-risk populations. This includes patients with a history of depression, suicidal ideation, or other significant mental illness, as Naltrexone may exacerbate these conditions.[22] Caution is also warranted in patients with pre-existing, non-acute liver disease (e.g., cirrhosis, chronic hepatitis B or C) or moderate-to-severe kidney disease. Impaired hepatic or renal function can slow the metabolism and elimination of the drug and its active metabolite, potentially increasing plasma concentrations and the risk of adverse effects.[12]

Critical Warnings and Precautions

There are three paramount safety warnings associated with Naltrexone therapy that require diligent patient education and clinical vigilance.

1. Precipitated Opioid Withdrawal: This is the most immediate and severe risk upon treatment initiation. As previously detailed, administering Naltrexone to an opioid-dependent individual will trigger an abrupt and intense withdrawal syndrome. Symptoms can include severe nausea, vomiting, diarrhea, muscle aches, anxiety, and autonomic instability. The reaction can be severe enough to require hospitalization.[1] This is the fundamental reason for the mandatory 7- to 10-day opioid-free washout period before the first dose.
2. Vulnerability to Opioid Overdose: This is a life-threatening risk that can occur both during and after Naltrexone treatment. Naltrexone works by blocking opioid receptors, but it also significantly reduces or eliminates a person's physiological tolerance to opioids over time.[15] If a patient relapses and uses opioids after a period of Naltrexone treatment (or even after missing a few doses of the oral form), their previous "usual" dose of heroin or pills can now be a fatal overdose. Patients and their families must be explicitly and repeatedly educated about this increased sensitivity.[14] Additionally, some patients may attempt to overcome the opioid blockade by taking massive doses of opioids. This is extremely dangerous and can lead to overwhelming the system, resulting in profound respiratory depression, circulatory collapse, coma, and death.[10]
3. Hepatotoxicity (Liver Injury): Naltrexone has been associated with hepatocellular injury, particularly at doses exceeding the recommended 50 mg per day.[53] While liver injury at standard therapeutic doses is uncommon, the risk exists, and the drug is contraindicated in patients with acute hepatitis or liver failure. Clinicians should consider monitoring liver function periodically during treatment. Patients should be instructed to stop taking Naltrexone and seek immediate medical attention if they develop signs or symptoms of acute hepatitis, such as persistent stomach pain, yellowing of the skin or eyes (jaundice), dark urine, or white/clay-colored stools.[11]

Clinically Significant Drug Interactions

Naltrexone's interaction profile is dominated by its powerful effects on the opioid system.

Table 5: Clinically Significant Drug and Disease Interactions with Naltrexone

Interacting Agent/Condition	Interaction Type	Clinical Consequence	Management Recommendation	Source(s)
All Opioid Medications (e.g., Morphine, Oxycodone, Heroin, Methadone, Buprenorphine, Codeine, Lomotil)	Major	1. Blocks analgesic effect of opioids. 2. Precipitates severe withdrawal in opioid-dependent individuals.	Combination is contraindicated. Ensure a 7-14 day opioid-free period before starting Naltrexone. Patients must inform all healthcare providers they are on Naltrexone.	11
Other Opioid Antagonists (e.g., Naloxone, Nalmefene, Naloxegol)	Moderate	Additive effects; may increase the risk of side effects.	Use with caution; monitor for increased adverse effects.	56
Disulfiram	Moderate	Both drugs carry a risk of hepatotoxicity; co-administration may increase the risk of liver injury.	Use with caution. Monitor liver function closely if combination is necessary.	56
Thioridazine	Moderate	May cause additive sedative effects and increase sleepiness.	Use with caution; advise patient of potential for increased drowsiness.	56
Acamprosate	Moderate	Naltrexone may increase the bioavailability and plasma levels of Acamprosate.	No dose adjustment is typically needed, but monitor for Acamprosate side effects.	1
Hepatic Dysfunction (Acute Hepatitis / Liver Failure)	Major (Disease Interaction)	Naltrexone is contraindicated due to risk of hepatotoxicity.	Do not use.	14
Hepatic/Renal Dysfunction (Chronic/Moderate)	Moderate (Disease Interaction)	Impaired drug clearance can lead to increased drug levels and higher risk of adverse effects.	Use with caution. Consider dose adjustments and monitor organ function.	22

Expanding Therapeutic Horizons: Off-Label and Investigational Uses

Beyond its established role in addiction medicine, Naltrexone has garnered significant interest for a wide range of other conditions, particularly when used at very low doses. This has revealed a second, distinct pharmacological identity for the drug, targeting pathways of inflammation and immune modulation that are entirely separate from its high-dose effects on the opioid system. This duality is a remarkable example of the hormetic principle in pharmacology, where a substance can exert qualitatively different or even opposite effects at different concentrations.[17]

The Paradigm of Low-Dose Naltrexone (LDN)

Low-Dose Naltrexone (LDN) refers to the use of Naltrexone at daily doses that are approximately one-tenth of the standard dose used for addiction treatment, typically ranging from 1 mg to 5 mg per day, with 4.5 mg being a common clinical dose.[17] At these low concentrations, Naltrexone exhibits paradoxical analgesic and anti-inflammatory properties that are not observed at higher doses.[60]

The proposed mechanism of action for LDN is fundamentally different from the competitive opioid receptor blockade that defines standard-dose Naltrexone. The leading hypothesis is that LDN functions as a novel glial cell modulator.[60] Specifically, it is believed to act as an antagonist at Toll-like receptor 4 (TLR4), a key receptor on the surface of microglia, the primary immune cells of the central nervous system.[17] By blocking TLR4 signaling, LDN is thought to downregulate the production of pro-inflammatory cytokines and other inflammatory mediators, thereby reducing neuroinflammation, which is increasingly implicated in the pathophysiology of chronic pain syndromes.[60] In vitro studies have confirmed that LDN can shift microglia from a pro-inflammatory (M1) phenotype to a quiescent, anti-inflammatory (M2) phenotype and alter their cellular metabolism accordingly.[3]

A secondary, complementary mechanism is also proposed. The brief, transient blockade of opioid receptors by a low dose of Naltrexone is thought to trigger a compensatory "rebound" effect in the body. This rebound involves the upregulation of the synthesis and release of endogenous opioids, namely endorphins and enkephalins, as well as an increase in the sensitivity of their receptors.[59] The result is an enhanced endogenous pain-relief system once the temporary blockade has worn off.

This discovery of a separate, dose-dependent pharmacological identity is profound. It effectively means that Naltrexone is not one drug, but two, depending on the dose administered. High-dose Naltrexone (50 mg) is an opioid receptor antagonist for treating addiction. Low-dose Naltrexone (1-5 mg) is an immunomodulatory, anti-inflammatory agent for treating chronic pain and inflammatory conditions. This represents a fascinating case of a drug being "repurposed" within itself and has significant implications for future pharmacological research, suggesting that other established drugs may possess hidden, dose-dependent mechanisms that could be harnessed for entirely new therapeutic purposes.

Evidence for LDN in Chronic Pain and Inflammatory Disorders

The unique mechanism of LDN has led to its investigation in a variety of conditions characterized by chronic pain and immune dysregulation.

Fibromyalgia: This is the most widely studied and promising off-label application for LDN.[59] Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction, and is thought to involve central sensitization and neuroinflammation. Multiple small-scale clinical trials, systematic reviews, and a large volume of anecdotal evidence suggest that LDN can provide significant relief for many patients.[59] Studies have reported reductions in pain, fatigue, and stress, along with improvements in sleep quality, mood, and overall quality of life.[61] The typical dosage is 4.5 mg per day, usually taken at bedtime, although it is often titrated up slowly from a lower starting dose (e.g., 1.5 mg) to improve tolerability.[61] LDN is generally very well-tolerated, with the most common side effects being mild and transient, such as vivid dreams, insomnia (which can be mitigated by morning dosing), or mild gastrointestinal upset.[59] While the existing evidence is highly encouraging, a major limitation is that it is primarily derived from small studies. There is a clear and urgent need for large-scale, robust, randomized controlled trials to definitively establish its efficacy and safety in this population.[60]

Crohn's Disease: As an inflammatory bowel disease, Crohn's is another logical target for LDN's anti-inflammatory properties.[66] A small number of placebo-controlled trials have been conducted. A key trial in adults with active Crohn's disease found that while LDN did not significantly increase the rate of clinical

remission compared to placebo, it did produce a statistically significant improvement in clinical response (i.e., reduction in symptoms) and endoscopic response (i.e., visible reduction in gut inflammation).[70] Another open-label study reported that 89% of patients experienced an improvement in quality of life and 67% achieved symptomatic remission.[66] As with fibromyalgia, the current body of evidence is considered insufficient to draw firm conclusions, but it suggests a potential therapeutic benefit with a favorable safety profile, warranting further investigation.[70]

Table 6: Summary of Clinical Evidence for Low-Dose Naltrexone (LDN) in Off-Label Indications

Condition	Proposed Mechanism of Action	Typical Dose	Key Study Findings	Level of Evidence	Source(s)
Fibromyalgia	Glial cell (TLR4) modulation; anti-inflammatory; endogenous opioid upregulation.	1.5–4.5 mg daily	Significant reductions in pain, fatigue, and stress; improved sleep and quality of life. Well-tolerated.	Preliminary; multiple small RCTs and systematic reviews.	59
Crohn's Disease	Anti-inflammatory; immune modulation; endorphin upregulation.	4.5 mg daily	Significant improvement in clinical and endoscopic response, but not remission. Improved quality of life.	Insufficient; two small RCTs.	66
Multiple Sclerosis	Glial cell modulation; anti-inflammatory.	1.5–4.5 mg daily	Improved mental health-related quality of life and disability.	Preliminary; small studies.	5
Long COVID	Anti-inflammatory; immune modulation.	Not established	Currently under investigation in small clinical trials.	Investigational.	5

Other Investigational Applications

The potential applications of Naltrexone, in both standard and low doses, extend to a variety of other conditions, primarily in the realms of psychiatry and behavioral health.

• Dissociative Disorders: Naltrexone has been used off-label to treat symptoms of depersonalization and derealization. This effect is thought to be mediated by its antagonist action at kappa-opioid receptors (KORs), which are implicated in dissociative states. Higher-than-standard doses may be required to achieve sufficient KOR blockade.[5]
• Impulse-Control and Behavioral Disorders: There is some preliminary evidence and case reports suggesting that Naltrexone may be beneficial in treating impulse-control disorders such as kleptomania, compulsive gambling, and trichotillomania (compulsive hair pulling), although the evidence for gambling is conflicting.[5] It may work by blunting the rewarding rush associated with these compulsive behaviors. Case studies have also reported its successful use in treating behavioral addictions, such as internet pornography addiction, and in reducing self-injurious behaviors in individuals with developmental disabilities like autism by blocking the reinforcing release of endorphins.[5]
• Other Conditions: Naltrexone is being explored for its potential to suppress the cytokine-mediated neuropsychiatric side effects of interferon alpha therapy.[5] There are also small studies suggesting it may help reduce problematic sexual behaviors and sexual addiction.[5] Finally, its immunomodulatory properties have led to its investigation as a potential treatment for symptoms of Long COVID, with several small trials underway.[5]

Synthesis and Expert Recommendations

Naltrexone stands as a remarkable pharmacological agent, distinguished by its dual identity as both a cornerstone therapy in addiction medicine and a promising novel treatment for chronic inflammatory conditions. Its journey from a simple opioid antagonist to a complex immunomodulator illustrates the dynamic nature of drug discovery and application. A comprehensive synthesis of the evidence reveals its established value, its limitations, and the critical directions for future research needed to fully realize its therapeutic potential.

Integrated View of Naltrexone's Role in Modern Medicine

A Foundational Tool in Addiction Treatment: In its standard-dose formulation (50 mg oral, 380 mg injectable), Naltrexone is an indispensable tool for the management of Alcohol Use Disorder and Opioid Use Disorder. Its primary value stems from its non-agonist mechanism, which eliminates any potential for abuse, dependence, or diversion. This makes it a uniquely suitable option for a wide range of clinical settings, including primary care offices, mental health clinics, and the criminal justice system, where agonist therapies may face logistical or philosophical barriers. The development of the long-acting injectable formulation, Vivitrol, was a transformative step, overcoming the critical challenge of patient adherence and cementing Naltrexone's role as an effective relapse-prevention therapy.

The Importance of Patient-Centered Application: The extensive body of clinical evidence makes it clear that Naltrexone is not a panacea. Its success is highly dependent on appropriate patient selection and its integration into a comprehensive treatment plan. The ideal candidate for Naltrexone therapy is motivated, has specific treatment goals that align with the drug's mechanism (e.g., reducing heavy drinking rather than just maintaining abstinence), and is capable of successfully navigating the often-difficult induction period, particularly for OUD. The most effective use of Naltrexone occurs when it is paired with robust psychosocial support, empowering patients with the behavioral skills needed to sustain recovery.

The Emerging Promise of a Novel Anti-Inflammatory: The discovery of Low-Dose Naltrexone's (LDN) distinct pharmacology represents a potential paradigm shift in the treatment of a host of chronic, centrally-mediated pain and inflammatory conditions, such as fibromyalgia and Crohn's disease. For these disorders, which are often poorly managed by existing therapies, LDN offers a low-cost, generally well-tolerated option that targets a novel pathophysiological pathway: glial cell modulation and neuroinflammation. While the evidence is still preliminary, the consistency of positive findings across multiple small studies has generated significant interest and hope in both the patient and clinical communities.

Future Research Directions and Unanswered Questions

To optimize the current use of Naltrexone and validate its emerging applications, several key areas of research must be prioritized.

1. Optimizing Initiation for Opioid Use Disorder: The single greatest barrier to the broader use of extended-release Naltrexone for OUD is the difficult initiation process. While the SWIFT trial provided a proof-of-concept for a more rapid protocol, further research is critically needed to refine these methods, improve their tolerability, and make them more feasible for implementation in standard community treatment settings. This is the most pressing unmet need for expanding Naltrexone's impact on the opioid crisis.
2. Validating the Efficacy of Low-Dose Naltrexone (LDN): The promise of LDN can only be fulfilled through rigorous scientific validation. There is an urgent need for large-scale, long-term, multi-center, randomized, placebo-controlled trials to definitively establish the efficacy and safety of LDN for its most promising indications, particularly fibromyalgia and Crohn's disease. Such studies are essential to move LDN from an off-label, experimental therapy to a recognized, evidence-based standard of care.
3. Long-Term Comparative Effectiveness Studies: While short-term comparative trials have provided valuable insights into how Naltrexone performs against Acamprosate (for AUD) and Buprenorphine (for OUD), there is a lack of long-term data. Studies with follow-up periods of 12 months or longer are needed to understand the persistence of therapeutic effects, long-term retention rates, and overall health and functional outcomes.
4. Advancing Pharmacogenomic Research: Preliminary evidence suggests that genetic variations, such as the A118G polymorphism in the mu-opioid receptor gene (OPRM1), may predict an individual's response to Naltrexone therapy.[12] Expanding research in this area could pave the way for a more personalized approach to addiction medicine, allowing clinicians to use genetic markers to identify which patients are most likely to benefit from Naltrexone, thereby improving treatment outcomes and optimizing the allocation of resources.

Works cited

1. Naltrexone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00704
2. Naltrexone | C20H23NO4 | CID 5360515 - PubChem, accessed July 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Naltrexone
3. Naltrexone | CAS#16590-41-3 | CAS#16676-29-2 | Antidote - MedKoo Biosciences, accessed July 18, 2025, https://www.medkoo.com/products/8665
4. CAS 16590-41-3 - Sigma-Aldrich, accessed July 18, 2025, https://www.sigmaaldrich.com/US/en/search/16590-41-3?focus=products&page=1&perpage=30&sort=relevance&term=16590-41-3&type=cas_number
5. Naltrexone - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Naltrexone
6. Chapter 4—Oral Naltrexone - Incorporating Alcohol ... - NCBI, accessed July 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK64042/
7. Naltrexone USP Reference Standard CAS 16590-41-3 Sigma-Aldrich, accessed July 18, 2025, https://www.sigmaaldrich.com/US/en/product/usp/1453504
8. [Naltrexone (200 mg)] - CAS [16590-41-3] - USP Store, accessed July 18, 2025, https://store.usp.org/product/1453504
9. go.drugbank.com, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00704#:~:text=Naltrexone%20is%20thought%20to%20act,the%20effects%20of%20endogenous%20opioids.
10. What is the mechanism of action for naltrexone? - Drugs.com, accessed July 18, 2025, https://www.drugs.com/medical-answers/mechanism-action-naltrexone-3571077/
11. What is the mechanism of action of Naltrexone (opioid receptor antagonist)? - Dr.Oracle, accessed July 18, 2025, https://www.droracle.ai/articles/36086/naltrexone-mechanism-of-action-
12. Naltrexone - StatPearls - NCBI Bookshelf, accessed July 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK534811/
13. Naltrexone Metabolism and Concomitant Drug Concentrations in Chronic Pain Patients | Journal of Analytical Toxicology | Oxford Academic, accessed July 18, 2025, https://academic.oup.com/jat/article/38/4/212/2798007
14. (naltrexone hydrochloride tablets USP) 50 mg Opioid Antagonist Rx only DESCRIPTION REVIA - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf
15. How Does Naltrexone Work for Opioid and Alcohol Use Disorder? - GoodRx, accessed July 18, 2025, https://www.goodrx.com/naltrexone/naltrexone-alcohol-drug-addiction-treatment
16. Naltrexone: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed July 18, 2025, https://www.drugs.com/naltrexone.html
17. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization - PMC - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6313374/
18. Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3490825/
19. 6β-Naltrexol - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/6%CE%B2-Naltrexol
20. Naltrexone Pharmacology, Pharmacokinetics, and Metabolism: Current Status, accessed July 18, 2025, https://www.tandfonline.com/doi/pdf/10.3109/00952997509005661
21. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice | Request PDF - ResearchGate, accessed July 18, 2025, https://www.researchgate.net/publication/26653465_6beta-naltrexol_preferentially_antagonizes_opioid_effects_on_gastrointestinal_transit_compared_to_antinociception_in_mice
22. Naltrexone (oral route) - Side effects & dosage - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/drugs-supplements/naltrexone-oral-route/description/drg-20068408
23. What Is Naltrexone? - UAMS Psychiatric Research Institute, accessed July 18, 2025, https://psychiatry.uams.edu/clinical-care/outpatient-care/cast/what-is-naltrexone/
24. Naltrexone (Revia®, Vivitrol®): Basic information - Simple and Practical Mental Health, accessed July 18, 2025, https://simpleandpractical.com/naltrexone-revia-vivitrol/
25. Vivitrol, ReVia (naltrexone) dosing, indications, interactions, adverse effects, and more, accessed July 18, 2025, https://reference.medscape.com/drug/vivitrol-revia-naltrexone-343333
26. Naltrexone Dosage for Alcohol and Opioid Abuse: Your GoodRx ..., accessed July 18, 2025, https://www.goodrx.com/naltrexone/dosage
27. The 4 Naltrexone Interactions You Should Know - GoodRx, accessed July 18, 2025, https://www.goodrx.com/naltrexone/interactions
28. Naltrexone Side Effects: 8 Risks to Know About - GoodRx, accessed July 18, 2025, https://www.goodrx.com/naltrexone/common-naltrexone-side-effects
29. Naltrexone Formulations in Correctional Settings - Health Management Associates, accessed July 18, 2025, https://www.healthmanagement.com/wp-content/uploads/IssueBriefNaltrexoneFormulations-FINAL.pdf
30. Long-Acting Treatment for Opioid Addiction Reduced Risk of Relapse, accessed July 18, 2025, https://www.columbiapsychiatry.org/news/long-acting-treatment-opioid-addiction-reduced-risk-relapse
31. VIVITROL® Dosing and Pharmacokinetics | HCP, accessed July 18, 2025, https://www.vivitrolhcp.com/dosing-and-pharmacokinetics
32. Naltrexone for alcohol dependence: a randomized controlled trial, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11784454/
33. Evidence about the use of naltrexone and for different ways of using ..., accessed July 18, 2025, https://academic.oup.com/alcalc/article/36/1/2/137995
34. Naltrexone Effective in Treatment of Alcoholism - AAFP, accessed July 18, 2025, https://www.aafp.org/pubs/afp/issues/2000/0215/p1134.html
35. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism - Oxford Academic, accessed July 18, 2025, https://academic.oup.com/alcalc/article-abstract/36/1/2/137995
36. Study Details | Naltrexone Treatment for Alcoholic Women | ClinicalTrials.gov, accessed July 18, 2025, https://clinicaltrials.gov/study/NCT00000448
37. A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders (AUD) - PMC - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5572298/
38. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8722377/
39. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial - Drug and Alcohol Findings, accessed July 18, 2025, https://findings.org.uk/PHP/dl.php?file=Lee_JD_7.cab&s=
40. Extended Release Naltrexone Prevents Opioid Relapse in Criminal ..., accessed July 18, 2025, https://www.recoveryanswers.org/research-post/extended-release-naltrexone-prevents-opioid-relapse-in-criminal-justice-offenders/
41. Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective | ScienceDaily, accessed July 18, 2025, https://www.sciencedaily.com/releases/2024/05/240508113058.htm
42. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/38717773/
43. Meta-analysis of naltrexone and acamprosate for treating alcohol ..., accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3970823/
44. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/23075288/
45. Naltrexone or acamprosate effective for alcohol use disorder | I.M. Matters Weekly, accessed July 18, 2025, https://immattersacp.org/weekly/archives/2023/11/14/1.htm
46. Review: in alcohol use disorders, acamprosate is more effective for inducing abstinence while naltrexone is more effective for reducing heavy drinking and craving - BMJ Mental Health, accessed July 18, 2025, https://mentalhealth.bmj.com/content/16/3/71
47. Unlocking the Battle: Naltrexone vs Buprenorphine - Which Addiction Treatment Reigns Supreme? - Tah Computing Solutions, accessed July 18, 2025, https://ktah.cs.lmu.edu/naltrexone-vs-buprenorphine
48. Suboxone, Methadone, Naltrexone: What's the Difference? - Hazelden Betty Ford Foundation, accessed July 18, 2025, https://www.hazeldenbettyford.org/articles/methadone-vs-suboxone-opioid-treatment
49. Two independent clinical trials compared the effectiveness of extended-release naltrexone (XR-NTX/VIVITROL®) versus buprenorphine-naloxone (BUP-NX) - Mass.gov, accessed July 18, 2025, https://www.mass.gov/doc/factsheet-lee-et-al-tanum-et-al-research-articles/download
50. Relative effectiveness of medications for opioid-related disorders: A ..., accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8970369/
51. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5274608/
52. Naltrexone for Alcoholism: Side Effects, Uses & Interactions - American Addiction Centers, accessed July 18, 2025, https://americanaddictioncenters.org/addiction-medications/naltrexone
53. What to avoid when taking naltrexone? - Drugs.com, accessed July 18, 2025, https://www.drugs.com/medical-answers/avoid-taking-naltrexone-3548600/
54. Acamprosate vs naltrexone: How do they compare? - Drugs.com, accessed July 18, 2025, https://www.drugs.com/medical-answers/acamprosate-naltrexone-compare-3571175/
55. What is Naltrexone? Side Effects, Uses, Dose & Risk | SAMHSA, accessed July 18, 2025, https://www.samhsa.gov/substance-use/treatment/options/naltrexone
56. Naltrexone tablet interactions: Other medications, alcohol, more, accessed July 18, 2025, https://www.medicalnewstoday.com/articles/naltrexone-tablet-interactions
57. Naltrexone Interactions Checker - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/naltrexone.html
58. Depade Interactions Checker - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/naltrexone,depade.html
59. Low-Dose Naltrexone: A Future Gold Medalist? - AAFP, accessed July 18, 2025, https://www.aafp.org/pubs/afp/afp-community-blog/entry/low-dose-naltrexone-a-future-gold-medalist.html
60. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3962576/
61. Low-dose naltrexone in the treatment of fibromyalgia: A systematic review and narrative synthesis - RACGP, accessed July 18, 2025, https://www1.racgp.org.au/ajgp/2023/april/low-dose-naltrexone-in-the-treatment-of-fibromyalg
62. What is LDN and Fibromyalgia? A Look at Low Dose Naltrexone - Swing Care, accessed July 18, 2025, https://www.swing.care/blog/what-is-ldn-and-fibromyalgia-a-look-at-low-dose-naltrexone/
63. Low Dose Naltrexone for Fibromyalgia | MoreGoodDays Pain-management Program, accessed July 18, 2025, https://www.moregooddays.com/post/low-dose-naltrexone-for-fibromyalgia
64. What You Need To Know About Low Dose Naltrexone | Patient Care, accessed July 18, 2025, https://weillcornell.org/news/what-you-need-to-know-about-low-dose-naltrexone
65. Low-Dose Naltrexone For Fibromyalgia - The Fibro Guy, accessed July 18, 2025, https://www.thefibroguy.com/blog/low-dose-naltrexone-for-fibromyalgia/
66. LDN – a potential Game Changer for Colitis or Crohn's Disease - Dispensaries pharmacy, accessed July 18, 2025, https://dispensariesltd.ca/health-hub/ldn-a-potential-game-changer-for-colitis-or-crohns-disease/
67. The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10039621/
68. Low-dose naltrexone in the treatment of fibromyalgia: A ... - RACGP, accessed July 18, 2025, https://www.racgp.org.au/ajgp/2023/april/low-dose-naltrexone-in-the-treatment-of-fibromyalg
69. Naltrexone for Fibromyalgia User Reviews - Drugs.com, accessed July 18, 2025, https://www.drugs.com/comments/naltrexone/for-fibromyalgia.html
70. Low dose naltrexone for induction of remission in Crohn's disease ..., accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6494424/